Peptide Hydrogel Drug Depots for Localized Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immunosuppressive drugs used in organ transplantation cause deleterious side effects and dose-limiting toxicity when administered systemically, necessitating improved strategies for local delivery to enhance graft survival.
Innovation Solution
Development of peptide hydrogels containing crystallized immunosuppressive small molecule drugs, such as tofacitinib, which allow for localized and sustained release of the drug at the administration site, minimizing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive drugs are administered systemically to prevent allograft rejection, then graft survival is improved, but drug-associated toxicity increases
Solution Approach 1:
The invention segments the drug delivery system into localized deposits at the graft site rather than systemic distribution. Immunosuppressive drugs are delivered as localized deposits directly at the allograft site, ensuring the drug acts where needed while minimizing exposure to other organs and tissues, thereby reducing systemic toxicity while maintaining graft protection.
Solution Approach 2:
The invention applies local quality by concentrating the immunosuppressive drug action specifically at the graft site. The localized delivery system ensures high drug concentration where it is most needed (at the allograft interface) while maintaining low systemic levels, creating a spatial gradient of drug presence that maximizes therapeutic effect and minimizes harmful side effects.
2Duration of action of stationary object
If immunosuppressive drugs are administered chronically to enhance transplant survival, then longer graft survival is achieved, but dose-limiting side effects occur
Solution Approach 1:
The invention implements preliminary action by establishing a reservoir of immunosuppressive drug at the graft site before rejection occurs. The localized deposits serve as a pre-positioned supply that releases drug chronically over time, providing sustained immunosuppression throughout the transplant lifecycle without requiring repeated systemic administrations that cause cumulative toxicity.
Solution Approach 2:
The invention ensures continuity of useful action through the sustained release mechanism of localized drug deposits. The immunosuppressive agents are released continuously at the graft site over extended periods, maintaining therapeutic levels necessary for long-term graft survival while avoiding the intermittent high-dose systemic administrations that lead to dose-limiting side effects.
3Reliability
If high doses of immunosuppressive drugs are administered to prevent rejection, then allograft survival is improved, but renal function impairment and other toxicities increase
Solution Approach 1:
The invention segments the drug delivery to concentrate high doses locally at the graft site rather than distributing them systemically. By depositing immunosuppressive drugs directly at the allograft interface, the system achieves high local concentrations necessary for preventing rejection while minimizing the drug burden on renal and other systemic organs, thereby avoiding renal function impairment and other toxicities.
Solution Approach 2:
The invention applies local quality by creating a spatial distinction between high drug concentration at the graft site and low systemic concentration. The localized deposits ensure that high doses are delivered precisely where needed to prevent rejection, while systemic exposure remains low, protecting renal function and reducing other dose-limiting toxicities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide hydrogel system enables effective inhibition of allograft rejection and autoimmune injury while reducing drug-associated toxicity, promoting longer graft survival and therapeutic efficacy.
Implementation Method 1
The compositions include a peptide hydrogel containing the immunosuppressive small molecule drug in crystalline form. Crystallization of the small molecule within the fibril network of the hydrogel results in sustained release of the drug at the site of administration.
Implementation Method 2
Compositions that allow for the local delivery of an immunosuppressive small molecule drug are described. The compositions include a peptide hydrogel containing the immunosuppressive small molecule drug in crystalline form.
Data Source
AI summary
Compositions that include a cationic peptide hydrogel and an immunosuppressive small molecule drug are described. The small molecule drug is crystallized and dispersed in the peptide hydrogel to allow for slow release of the drug. Methods of inhibiting allograft rejection and treating autoimmune-mediated organ damage by local administration of the peptide hydrogel compositions are described.